Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(Imatinib). Showing records 1 – 30 of 79 total matches.

[1] [2] [3]

Search Limiters

Last 2 Years | English Only

Degrees

Levels

Languages

Country

▼ Search Limiters


Vanderbilt University

1. Frappier, Sara Lynn. MALDI Imaging Mass Spectrometry for small molecule quantitation and evaluation for markers of drug response in Gliomas.

Degree: PhD, Chemistry, 2011, Vanderbilt University

 MALDI IMAGING MASS SPECTROMETRY FOR SMALL MOLECULE QUANTITATION AND EVALUATION FOR MARKERS OF DRUG RESPONSE IN GLIOMAS SARA L. FRAPPIER Dissertation under the direction of… (more)

Subjects/Keywords: PROTEOMICS; CYCLOPAMINE; IMATINIB

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Frappier, S. L. (2011). MALDI Imaging Mass Spectrometry for small molecule quantitation and evaluation for markers of drug response in Gliomas. (Doctoral Dissertation). Vanderbilt University. Retrieved from http://etd.library.vanderbilt.edu/available/etd-03282011-103836/ ;

Chicago Manual of Style (16th Edition):

Frappier, Sara Lynn. “MALDI Imaging Mass Spectrometry for small molecule quantitation and evaluation for markers of drug response in Gliomas.” 2011. Doctoral Dissertation, Vanderbilt University. Accessed December 11, 2019. http://etd.library.vanderbilt.edu/available/etd-03282011-103836/ ;.

MLA Handbook (7th Edition):

Frappier, Sara Lynn. “MALDI Imaging Mass Spectrometry for small molecule quantitation and evaluation for markers of drug response in Gliomas.” 2011. Web. 11 Dec 2019.

Vancouver:

Frappier SL. MALDI Imaging Mass Spectrometry for small molecule quantitation and evaluation for markers of drug response in Gliomas. [Internet] [Doctoral dissertation]. Vanderbilt University; 2011. [cited 2019 Dec 11]. Available from: http://etd.library.vanderbilt.edu/available/etd-03282011-103836/ ;.

Council of Science Editors:

Frappier SL. MALDI Imaging Mass Spectrometry for small molecule quantitation and evaluation for markers of drug response in Gliomas. [Doctoral Dissertation]. Vanderbilt University; 2011. Available from: http://etd.library.vanderbilt.edu/available/etd-03282011-103836/ ;

2. Pereira, João Pedro. Farmacogenética na terapêutica das leucemias.

Degree: 2014, RCAAP

Dissertação para obtenção do grau de Mestre no Instituto Superior de Ciências da Saúde Egas Moniz

A leucemia é uma doença neoplásica que afecta a… (more)

Subjects/Keywords: Leucemia; Farmacogenética; SNP; Imatinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Pereira, J. P. (2014). Farmacogenética na terapêutica das leucemias. (Thesis). RCAAP. Retrieved from https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/13058

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Pereira, João Pedro. “Farmacogenética na terapêutica das leucemias.” 2014. Thesis, RCAAP. Accessed December 11, 2019. https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/13058.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Pereira, João Pedro. “Farmacogenética na terapêutica das leucemias.” 2014. Web. 11 Dec 2019.

Vancouver:

Pereira JP. Farmacogenética na terapêutica das leucemias. [Internet] [Thesis]. RCAAP; 2014. [cited 2019 Dec 11]. Available from: https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/13058.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Pereira JP. Farmacogenética na terapêutica das leucemias. [Thesis]. RCAAP; 2014. Available from: https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/13058

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Universitat de Valencia

3. Amat Martínez, Paula. Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica .

Degree: 2016, Universitat de Valencia

 La leucemia mieloide crónica (LMC) es una neoplasia mieloproliferativa crónica de carácter clonal con origen en una célula madre pluripotencial común a las tres series… (more)

Subjects/Keywords: leucemia mieloide crónica; SNP; imatinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Amat Martínez, P. (2016). Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica . (Doctoral Dissertation). Universitat de Valencia. Retrieved from http://hdl.handle.net/10550/50156

Chicago Manual of Style (16th Edition):

Amat Martínez, Paula. “Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica .” 2016. Doctoral Dissertation, Universitat de Valencia. Accessed December 11, 2019. http://hdl.handle.net/10550/50156.

MLA Handbook (7th Edition):

Amat Martínez, Paula. “Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica .” 2016. Web. 11 Dec 2019.

Vancouver:

Amat Martínez P. Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica . [Internet] [Doctoral dissertation]. Universitat de Valencia; 2016. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/10550/50156.

Council of Science Editors:

Amat Martínez P. Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica . [Doctoral Dissertation]. Universitat de Valencia; 2016. Available from: http://hdl.handle.net/10550/50156


University of Adelaide

4. Khan, Muhammad Suleman. Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib.

Degree: 2015, University of Adelaide

Imatinib is a first line therapy for the treatment of chronic myeloid leukaemia (CML). Treatment with imatinib must be continuous and indefinite for most patients… (more)

Subjects/Keywords: CYP2C8; Biotransformation; imatinib; N-desmethyl imatinib; pharmacogenetics; Research by Publication

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Khan, M. S. (2015). Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib. (Thesis). University of Adelaide. Retrieved from http://hdl.handle.net/2440/105021

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Khan, Muhammad Suleman. “Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib.” 2015. Thesis, University of Adelaide. Accessed December 11, 2019. http://hdl.handle.net/2440/105021.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Khan, Muhammad Suleman. “Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib.” 2015. Web. 11 Dec 2019.

Vancouver:

Khan MS. Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib. [Internet] [Thesis]. University of Adelaide; 2015. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/2440/105021.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Khan MS. Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib. [Thesis]. University of Adelaide; 2015. Available from: http://hdl.handle.net/2440/105021

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Adelaide

5. Vandyke, Kate. The effects of tyrosine kinase inhibition on bone remodelling.

Degree: 2010, University of Adelaide

Imatinib is a rationally-designed tyrosine kinase inhibitor that is a highly-successful treatment for chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours. In a retrospective study,… (more)

Subjects/Keywords: bone remodelling; osteoclasts; osteoblasts; chondrocytes; imatinib; dasatinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Vandyke, K. (2010). The effects of tyrosine kinase inhibition on bone remodelling. (Thesis). University of Adelaide. Retrieved from http://hdl.handle.net/2440/65627

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Vandyke, Kate. “The effects of tyrosine kinase inhibition on bone remodelling.” 2010. Thesis, University of Adelaide. Accessed December 11, 2019. http://hdl.handle.net/2440/65627.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Vandyke, Kate. “The effects of tyrosine kinase inhibition on bone remodelling.” 2010. Web. 11 Dec 2019.

Vancouver:

Vandyke K. The effects of tyrosine kinase inhibition on bone remodelling. [Internet] [Thesis]. University of Adelaide; 2010. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/2440/65627.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Vandyke K. The effects of tyrosine kinase inhibition on bone remodelling. [Thesis]. University of Adelaide; 2010. Available from: http://hdl.handle.net/2440/65627

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Adelaide

6. Tang, Carine. TKI resistance in CML cell lines : investigating resistance pathways.

Degree: 2012, University of Adelaide

 Chronic myeloid leukaemia (CML) is characterised by the presence of the Philadelphia chromosome which harbours the Bcr-Abl oncogene. BCR-ABL is a constitutively active tyrosine kinase… (more)

Subjects/Keywords: CML; imatinib; nilotinib; dasatinib; TKI; resistance

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Tang, C. (2012). TKI resistance in CML cell lines : investigating resistance pathways. (Thesis). University of Adelaide. Retrieved from http://hdl.handle.net/2440/82443

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Tang, Carine. “TKI resistance in CML cell lines : investigating resistance pathways.” 2012. Thesis, University of Adelaide. Accessed December 11, 2019. http://hdl.handle.net/2440/82443.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Tang, Carine. “TKI resistance in CML cell lines : investigating resistance pathways.” 2012. Web. 11 Dec 2019.

Vancouver:

Tang C. TKI resistance in CML cell lines : investigating resistance pathways. [Internet] [Thesis]. University of Adelaide; 2012. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/2440/82443.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Tang C. TKI resistance in CML cell lines : investigating resistance pathways. [Thesis]. University of Adelaide; 2012. Available from: http://hdl.handle.net/2440/82443

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Arizona State University

7. Arkus, Nohea Lauae Ananda. Addicted to Autophagy: Ph+ B-ALL May Acquire Imatinib-resistance and Enhanced Malignancy through a Highly-active Autophagy Pathway.

Degree: MS, Biological Design, 2011, Arizona State University

 The majority of chronic myeloid leukemia (CML) and some of acute lymphocytic leukemia (ALL) cases are associated with possessing the BCR-Abl fusion protein from an… (more)

Subjects/Keywords: Molecular Biology; Oncology; ALL; ARF; autophagy; Imatinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Arkus, N. L. A. (2011). Addicted to Autophagy: Ph+ B-ALL May Acquire Imatinib-resistance and Enhanced Malignancy through a Highly-active Autophagy Pathway. (Masters Thesis). Arizona State University. Retrieved from http://repository.asu.edu/items/9272

Chicago Manual of Style (16th Edition):

Arkus, Nohea Lauae Ananda. “Addicted to Autophagy: Ph+ B-ALL May Acquire Imatinib-resistance and Enhanced Malignancy through a Highly-active Autophagy Pathway.” 2011. Masters Thesis, Arizona State University. Accessed December 11, 2019. http://repository.asu.edu/items/9272.

MLA Handbook (7th Edition):

Arkus, Nohea Lauae Ananda. “Addicted to Autophagy: Ph+ B-ALL May Acquire Imatinib-resistance and Enhanced Malignancy through a Highly-active Autophagy Pathway.” 2011. Web. 11 Dec 2019.

Vancouver:

Arkus NLA. Addicted to Autophagy: Ph+ B-ALL May Acquire Imatinib-resistance and Enhanced Malignancy through a Highly-active Autophagy Pathway. [Internet] [Masters thesis]. Arizona State University; 2011. [cited 2019 Dec 11]. Available from: http://repository.asu.edu/items/9272.

Council of Science Editors:

Arkus NLA. Addicted to Autophagy: Ph+ B-ALL May Acquire Imatinib-resistance and Enhanced Malignancy through a Highly-active Autophagy Pathway. [Masters Thesis]. Arizona State University; 2011. Available from: http://repository.asu.edu/items/9272

8. Bardin, Christophe. Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib : Evaluation of different size-descriptors in obese subjects using population pharmacokinetic model : application to metformin, morphine, imatinib.

Degree: Docteur es, Pharmacologie, 2012, Université Paris Descartes – Paris V

Les modifications physiopathologiques induites par l’obésité sont susceptibles de modifier la pharmacocinétique d’un grand nombre de médicaments. Toutes les étapes peuvent-être touchées : modification des… (more)

Subjects/Keywords: Pharmacocinétique de population; Obésité; Imatinib; Morphine; Metformine; Population pharmacokinetics; Obesity; Imatinib; Morphine; Metformin; 616.398 061

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Bardin, C. (2012). Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib : Evaluation of different size-descriptors in obese subjects using population pharmacokinetic model : application to metformin, morphine, imatinib. (Doctoral Dissertation). Université Paris Descartes – Paris V. Retrieved from http://www.theses.fr/2012PA05P649

Chicago Manual of Style (16th Edition):

Bardin, Christophe. “Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib : Evaluation of different size-descriptors in obese subjects using population pharmacokinetic model : application to metformin, morphine, imatinib.” 2012. Doctoral Dissertation, Université Paris Descartes – Paris V. Accessed December 11, 2019. http://www.theses.fr/2012PA05P649.

MLA Handbook (7th Edition):

Bardin, Christophe. “Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib : Evaluation of different size-descriptors in obese subjects using population pharmacokinetic model : application to metformin, morphine, imatinib.” 2012. Web. 11 Dec 2019.

Vancouver:

Bardin C. Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib : Evaluation of different size-descriptors in obese subjects using population pharmacokinetic model : application to metformin, morphine, imatinib. [Internet] [Doctoral dissertation]. Université Paris Descartes – Paris V; 2012. [cited 2019 Dec 11]. Available from: http://www.theses.fr/2012PA05P649.

Council of Science Editors:

Bardin C. Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib : Evaluation of different size-descriptors in obese subjects using population pharmacokinetic model : application to metformin, morphine, imatinib. [Doctoral Dissertation]. Université Paris Descartes – Paris V; 2012. Available from: http://www.theses.fr/2012PA05P649

9. Allard, Diane d'. Erythropoïèse normale et pathologique, internalisation de c-Kit et morphologie du nucléole : Normal and pathologic erythropoiesis, c-Kit internalization and nucleolus morphology.

Degree: Docteur es, Hématologie et oncologie, 2013, Université Paris Descartes – Paris V

 L’érythropoïèse est le processus aboutissant à la production des hématies à partir d’une cellule souche hématopoïétique. La différenciation érythroïde implique des changements morphologiques en partie… (more)

Subjects/Keywords: Différenciation érythroïde; C-Kit; Imatinib; Nucléoles; SMD; Erythroid differentiation; C-Kit; Imatinib; Nucleoli; MDS; 616.151

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Allard, D. d. (2013). Erythropoïèse normale et pathologique, internalisation de c-Kit et morphologie du nucléole : Normal and pathologic erythropoiesis, c-Kit internalization and nucleolus morphology. (Doctoral Dissertation). Université Paris Descartes – Paris V. Retrieved from http://www.theses.fr/2013PA05S026

Chicago Manual of Style (16th Edition):

Allard, Diane d'. “Erythropoïèse normale et pathologique, internalisation de c-Kit et morphologie du nucléole : Normal and pathologic erythropoiesis, c-Kit internalization and nucleolus morphology.” 2013. Doctoral Dissertation, Université Paris Descartes – Paris V. Accessed December 11, 2019. http://www.theses.fr/2013PA05S026.

MLA Handbook (7th Edition):

Allard, Diane d'. “Erythropoïèse normale et pathologique, internalisation de c-Kit et morphologie du nucléole : Normal and pathologic erythropoiesis, c-Kit internalization and nucleolus morphology.” 2013. Web. 11 Dec 2019.

Vancouver:

Allard Dd. Erythropoïèse normale et pathologique, internalisation de c-Kit et morphologie du nucléole : Normal and pathologic erythropoiesis, c-Kit internalization and nucleolus morphology. [Internet] [Doctoral dissertation]. Université Paris Descartes – Paris V; 2013. [cited 2019 Dec 11]. Available from: http://www.theses.fr/2013PA05S026.

Council of Science Editors:

Allard Dd. Erythropoïèse normale et pathologique, internalisation de c-Kit et morphologie du nucléole : Normal and pathologic erythropoiesis, c-Kit internalization and nucleolus morphology. [Doctoral Dissertation]. Université Paris Descartes – Paris V; 2013. Available from: http://www.theses.fr/2013PA05S026

10. Dufresne, Armelle. Une étude des voies de signalisation impliquées dans la carcinogénèse et le traitement des fibromatoses agressives : A study of signaling pathways involved in carcinogenesis and treatment of aggressive fibromatosis.

Degree: Docteur es, Oncologie, 2014, Université Claude Bernard – Lyon I

Les fibromatoses agressives sont des tumeurs conjonctives rares, pouvant envahir les structures adjacentes parfois de manière très agressive et responsables de fréquentes récidives loco-régionales mais… (more)

Subjects/Keywords: Tumeur desmoïde; Fibromatose agressive; Facteur pronostique; Facteur prédictif; Imatinib mésylate; Tumor desmoid; Aggressive fibromatose; Prognostic factor; Predictive factor; Imatinib mesylate; 616.994

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Dufresne, A. (2014). Une étude des voies de signalisation impliquées dans la carcinogénèse et le traitement des fibromatoses agressives : A study of signaling pathways involved in carcinogenesis and treatment of aggressive fibromatosis. (Doctoral Dissertation). Université Claude Bernard – Lyon I. Retrieved from http://www.theses.fr/2014LYO10082

Chicago Manual of Style (16th Edition):

Dufresne, Armelle. “Une étude des voies de signalisation impliquées dans la carcinogénèse et le traitement des fibromatoses agressives : A study of signaling pathways involved in carcinogenesis and treatment of aggressive fibromatosis.” 2014. Doctoral Dissertation, Université Claude Bernard – Lyon I. Accessed December 11, 2019. http://www.theses.fr/2014LYO10082.

MLA Handbook (7th Edition):

Dufresne, Armelle. “Une étude des voies de signalisation impliquées dans la carcinogénèse et le traitement des fibromatoses agressives : A study of signaling pathways involved in carcinogenesis and treatment of aggressive fibromatosis.” 2014. Web. 11 Dec 2019.

Vancouver:

Dufresne A. Une étude des voies de signalisation impliquées dans la carcinogénèse et le traitement des fibromatoses agressives : A study of signaling pathways involved in carcinogenesis and treatment of aggressive fibromatosis. [Internet] [Doctoral dissertation]. Université Claude Bernard – Lyon I; 2014. [cited 2019 Dec 11]. Available from: http://www.theses.fr/2014LYO10082.

Council of Science Editors:

Dufresne A. Une étude des voies de signalisation impliquées dans la carcinogénèse et le traitement des fibromatoses agressives : A study of signaling pathways involved in carcinogenesis and treatment of aggressive fibromatosis. [Doctoral Dissertation]. Université Claude Bernard – Lyon I; 2014. Available from: http://www.theses.fr/2014LYO10082

11. Stella, Stefania. Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato.

Degree: 2012, Università degli Studi di Catania

 L imatinib Mesilato ha mostrato una notevole efficacia nel trattamento della Leucemia Mieloide Cronica (LMC). In ogni caso, un numero crescente di pazienti fallisce il… (more)

Subjects/Keywords: Area 06 - Scienze mediche; CML, BCR-ABL, Imatinib, Resistance

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Stella, S. (2012). Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato. (Thesis). Università degli Studi di Catania. Retrieved from http://hdl.handle.net/10761/1139

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Stella, Stefania. “Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato.” 2012. Thesis, Università degli Studi di Catania. Accessed December 11, 2019. http://hdl.handle.net/10761/1139.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Stella, Stefania. “Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato.” 2012. Web. 11 Dec 2019.

Vancouver:

Stella S. Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato. [Internet] [Thesis]. Università degli Studi di Catania; 2012. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/10761/1139.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Stella S. Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato. [Thesis]. Università degli Studi di Catania; 2012. Available from: http://hdl.handle.net/10761/1139

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Temple University

12. Barr, Larry A. The Role of Calcium in the Regulation of Pathological Hypertrophy.

Degree: PhD, 2014, Temple University

Physiology

Pathological hypertrophy leads to cardiac dysfunction and heart failure. It is not clearly defined how this process occurs in the cardiomyocyte, or how the… (more)

Subjects/Keywords: Physiology; Molecular biology; Pharmacology;

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Barr, L. A. (2014). The Role of Calcium in the Regulation of Pathological Hypertrophy. (Doctoral Dissertation). Temple University. Retrieved from http://digital.library.temple.edu/u?/p245801coll10,254617

Chicago Manual of Style (16th Edition):

Barr, Larry A. “The Role of Calcium in the Regulation of Pathological Hypertrophy.” 2014. Doctoral Dissertation, Temple University. Accessed December 11, 2019. http://digital.library.temple.edu/u?/p245801coll10,254617.

MLA Handbook (7th Edition):

Barr, Larry A. “The Role of Calcium in the Regulation of Pathological Hypertrophy.” 2014. Web. 11 Dec 2019.

Vancouver:

Barr LA. The Role of Calcium in the Regulation of Pathological Hypertrophy. [Internet] [Doctoral dissertation]. Temple University; 2014. [cited 2019 Dec 11]. Available from: http://digital.library.temple.edu/u?/p245801coll10,254617.

Council of Science Editors:

Barr LA. The Role of Calcium in the Regulation of Pathological Hypertrophy. [Doctoral Dissertation]. Temple University; 2014. Available from: http://digital.library.temple.edu/u?/p245801coll10,254617


Universiteit Utrecht

13. Klümpen, H.J. Personalized medicine of targeted anti-cancer drugs.

Degree: 2012, Universiteit Utrecht

 Medicine is becoming more and more tailored and that certainly applies to therapies for cancer. The researcher has looked at the genetic profile of the… (more)

Subjects/Keywords: Farmacie; pharmacogenetics; pharmacodynamics; targeted therapies; mTOR inhibitors; imatinib; sunitinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Klümpen, H. J. (2012). Personalized medicine of targeted anti-cancer drugs. (Doctoral Dissertation). Universiteit Utrecht. Retrieved from http://dspace.library.uu.nl:8080/handle/1874/234354

Chicago Manual of Style (16th Edition):

Klümpen, H J. “Personalized medicine of targeted anti-cancer drugs.” 2012. Doctoral Dissertation, Universiteit Utrecht. Accessed December 11, 2019. http://dspace.library.uu.nl:8080/handle/1874/234354.

MLA Handbook (7th Edition):

Klümpen, H J. “Personalized medicine of targeted anti-cancer drugs.” 2012. Web. 11 Dec 2019.

Vancouver:

Klümpen HJ. Personalized medicine of targeted anti-cancer drugs. [Internet] [Doctoral dissertation]. Universiteit Utrecht; 2012. [cited 2019 Dec 11]. Available from: http://dspace.library.uu.nl:8080/handle/1874/234354.

Council of Science Editors:

Klümpen HJ. Personalized medicine of targeted anti-cancer drugs. [Doctoral Dissertation]. Universiteit Utrecht; 2012. Available from: http://dspace.library.uu.nl:8080/handle/1874/234354

14. Amat Martínez, Paula. Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica.

Degree: 2018, TDX

 La leucemia mieloide crónica (LMC) es una neoplasia mieloproliferativa crónica de carácter clonal con origen en una célula madre pluripotencial común a las tres series… (more)

Subjects/Keywords: leucemia mieloide crónica; SNP; imatinib; UNESCO::CIENCIAS MÉDICAS ::Patología::Hematología

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Amat Martínez, P. (2018). Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica. (Thesis). TDX. Retrieved from http://hdl.handle.net/10803/570461

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Amat Martínez, Paula. “Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica.” 2018. Thesis, TDX. Accessed December 11, 2019. http://hdl.handle.net/10803/570461.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Amat Martínez, Paula. “Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica.” 2018. Web. 11 Dec 2019.

Vancouver:

Amat Martínez P. Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica. [Internet] [Thesis]. TDX; 2018. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/10803/570461.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Amat Martínez P. Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica. [Thesis]. TDX; 2018. Available from: http://hdl.handle.net/10803/570461

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Adelaide

15. Engler, Jane. Cell lineage, cell maturity and BCR-ABL: factors which influence imatinib uptake in chronic myeloid leukaemia.

Degree: 2011, University of Adelaide

 Despite the excellent responses observed in patients with chronic phase (CP) chronic myeloid leukaemia (CML) on imatinib therapy, approximately 25% display primary resistance or suboptimal… (more)

Subjects/Keywords: chronic myeloid leukaemia; imatinib; CD34; organic cation transporter 1; BCR-ABL

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Engler, J. (2011). Cell lineage, cell maturity and BCR-ABL: factors which influence imatinib uptake in chronic myeloid leukaemia. (Thesis). University of Adelaide. Retrieved from http://hdl.handle.net/2440/70451

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Engler, Jane. “Cell lineage, cell maturity and BCR-ABL: factors which influence imatinib uptake in chronic myeloid leukaemia.” 2011. Thesis, University of Adelaide. Accessed December 11, 2019. http://hdl.handle.net/2440/70451.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Engler, Jane. “Cell lineage, cell maturity and BCR-ABL: factors which influence imatinib uptake in chronic myeloid leukaemia.” 2011. Web. 11 Dec 2019.

Vancouver:

Engler J. Cell lineage, cell maturity and BCR-ABL: factors which influence imatinib uptake in chronic myeloid leukaemia. [Internet] [Thesis]. University of Adelaide; 2011. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/2440/70451.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Engler J. Cell lineage, cell maturity and BCR-ABL: factors which influence imatinib uptake in chronic myeloid leukaemia. [Thesis]. University of Adelaide; 2011. Available from: http://hdl.handle.net/2440/70451

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Linköping University

16. Andersson, Anna. Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours.

Degree: Medical Programme, 2008, Linköping University

  Background: GISTs are gastrointestinal mesenchymal tumours that express the type III receptor tyrosine kinase KIT. The KIT proto-oncogene encodes the receptor KIT. Most GISTs… (more)

Subjects/Keywords: GIST; imatinib; adjuvant; down-staging; neoadjuvant; mutation; KIT; PDGFRA; Medicine; Medicin

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Andersson, A. (2008). Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours. (Thesis). Linköping University. Retrieved from http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-11060

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Andersson, Anna. “Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours.” 2008. Thesis, Linköping University. Accessed December 11, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-11060.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Andersson, Anna. “Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours.” 2008. Web. 11 Dec 2019.

Vancouver:

Andersson A. Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours. [Internet] [Thesis]. Linköping University; 2008. [cited 2019 Dec 11]. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-11060.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Andersson A. Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours. [Thesis]. Linköping University; 2008. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-11060

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of New South Wales

17. Loi, To Ha. Gene expression profiling in Philadelphia positive acute lymphoblastic leukaemia treated with Imatinib  – a novel role of PKC epsilon signalling.

Degree: Clinical School - St Vincent's Hospital, 2008, University of New South Wales

 Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) is characterised by the presence of the BCR-ABL fusion gene, which encodes a protein tyrosine kinase with aberrant… (more)

Subjects/Keywords: Microarray; Ph+ ALL; Imatinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Loi, T. H. (2008). Gene expression profiling in Philadelphia positive acute lymphoblastic leukaemia treated with Imatinib  – a novel role of PKC epsilon signalling. (Doctoral Dissertation). University of New South Wales. Retrieved from http://handle.unsw.edu.au/1959.4/43343 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:5144/SOURCE02?view=true

Chicago Manual of Style (16th Edition):

Loi, To Ha. “Gene expression profiling in Philadelphia positive acute lymphoblastic leukaemia treated with Imatinib  – a novel role of PKC epsilon signalling.” 2008. Doctoral Dissertation, University of New South Wales. Accessed December 11, 2019. http://handle.unsw.edu.au/1959.4/43343 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:5144/SOURCE02?view=true.

MLA Handbook (7th Edition):

Loi, To Ha. “Gene expression profiling in Philadelphia positive acute lymphoblastic leukaemia treated with Imatinib  – a novel role of PKC epsilon signalling.” 2008. Web. 11 Dec 2019.

Vancouver:

Loi TH. Gene expression profiling in Philadelphia positive acute lymphoblastic leukaemia treated with Imatinib  – a novel role of PKC epsilon signalling. [Internet] [Doctoral dissertation]. University of New South Wales; 2008. [cited 2019 Dec 11]. Available from: http://handle.unsw.edu.au/1959.4/43343 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:5144/SOURCE02?view=true.

Council of Science Editors:

Loi TH. Gene expression profiling in Philadelphia positive acute lymphoblastic leukaemia treated with Imatinib  – a novel role of PKC epsilon signalling. [Doctoral Dissertation]. University of New South Wales; 2008. Available from: http://handle.unsw.edu.au/1959.4/43343 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:5144/SOURCE02?view=true


University of New South Wales

18. Kumar, Shaun. Exploring the value of population pharmacokinetic and pharmacodynamic modelling: in infectious disease, cancer and diabetes.

Degree: Medical Sciences, 2016, University of New South Wales

 Dose selection is a critical part of individualising pharmacotherapy in order to ensure optimal safety and effectiveness. Population pharmacokinetic and/or pharmacodynamic modelling paired with Bayesian… (more)

Subjects/Keywords: Population pharmacodynamics; Pharmacometrics; Population pharmacokinetics; Ribavirin; Imatinib; Metformin; Dose individualisation

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kumar, S. (2016). Exploring the value of population pharmacokinetic and pharmacodynamic modelling: in infectious disease, cancer and diabetes. (Doctoral Dissertation). University of New South Wales. Retrieved from http://handle.unsw.edu.au/1959.4/55575 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:38076/SOURCE02?view=true

Chicago Manual of Style (16th Edition):

Kumar, Shaun. “Exploring the value of population pharmacokinetic and pharmacodynamic modelling: in infectious disease, cancer and diabetes.” 2016. Doctoral Dissertation, University of New South Wales. Accessed December 11, 2019. http://handle.unsw.edu.au/1959.4/55575 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:38076/SOURCE02?view=true.

MLA Handbook (7th Edition):

Kumar, Shaun. “Exploring the value of population pharmacokinetic and pharmacodynamic modelling: in infectious disease, cancer and diabetes.” 2016. Web. 11 Dec 2019.

Vancouver:

Kumar S. Exploring the value of population pharmacokinetic and pharmacodynamic modelling: in infectious disease, cancer and diabetes. [Internet] [Doctoral dissertation]. University of New South Wales; 2016. [cited 2019 Dec 11]. Available from: http://handle.unsw.edu.au/1959.4/55575 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:38076/SOURCE02?view=true.

Council of Science Editors:

Kumar S. Exploring the value of population pharmacokinetic and pharmacodynamic modelling: in infectious disease, cancer and diabetes. [Doctoral Dissertation]. University of New South Wales; 2016. Available from: http://handle.unsw.edu.au/1959.4/55575 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:38076/SOURCE02?view=true


University of Toronto

19. Lau, Mandy. Long-term Changes in Alveolarization in the Postnatal Rat Following Transient Inhibition of Early "Classical" Alveologenesis.

Degree: 2010, University of Toronto

Rationale: Activation of the platelet-derived growth factor receptors-α and -β (PDGF-Rα and -Rβ) is critical in the formation of secondary crests/septa during alveologenesis, and its… (more)

Subjects/Keywords: alveolarization; lung development; alveologenesis; secondary crests; septation; imatinib; 0719; 0433

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Lau, M. (2010). Long-term Changes in Alveolarization in the Postnatal Rat Following Transient Inhibition of Early "Classical" Alveologenesis. (Masters Thesis). University of Toronto. Retrieved from http://hdl.handle.net/1807/24258

Chicago Manual of Style (16th Edition):

Lau, Mandy. “Long-term Changes in Alveolarization in the Postnatal Rat Following Transient Inhibition of Early "Classical" Alveologenesis.” 2010. Masters Thesis, University of Toronto. Accessed December 11, 2019. http://hdl.handle.net/1807/24258.

MLA Handbook (7th Edition):

Lau, Mandy. “Long-term Changes in Alveolarization in the Postnatal Rat Following Transient Inhibition of Early "Classical" Alveologenesis.” 2010. Web. 11 Dec 2019.

Vancouver:

Lau M. Long-term Changes in Alveolarization in the Postnatal Rat Following Transient Inhibition of Early "Classical" Alveologenesis. [Internet] [Masters thesis]. University of Toronto; 2010. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/1807/24258.

Council of Science Editors:

Lau M. Long-term Changes in Alveolarization in the Postnatal Rat Following Transient Inhibition of Early "Classical" Alveologenesis. [Masters Thesis]. University of Toronto; 2010. Available from: http://hdl.handle.net/1807/24258


Universidad de Chile

20. Sasso Aguirre, Jaime Alfredo. Estudio de Biodisponibilidad Relativa de una Formulación Oral de Imatinib Respecto al Producto Innovador .

Degree: 2008, Universidad de Chile

 En este estudio se determinó la biodisponibilidad relativa para la bioequivalencia del producto similar Zeite® de Laboratorios Recalcine S.A., producto de prueba, con Glivec® fabricado… (more)

Subjects/Keywords: Química Farmacéutica; Biodisponibilidad; Imatinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Sasso Aguirre, J. A. (2008). Estudio de Biodisponibilidad Relativa de una Formulación Oral de Imatinib Respecto al Producto Innovador . (Thesis). Universidad de Chile. Retrieved from http://www.tesis.uchile.cl/tesis/uchile/2008/sasso_j/html/index-frames.html

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Sasso Aguirre, Jaime Alfredo. “Estudio de Biodisponibilidad Relativa de una Formulación Oral de Imatinib Respecto al Producto Innovador .” 2008. Thesis, Universidad de Chile. Accessed December 11, 2019. http://www.tesis.uchile.cl/tesis/uchile/2008/sasso_j/html/index-frames.html.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Sasso Aguirre, Jaime Alfredo. “Estudio de Biodisponibilidad Relativa de una Formulación Oral de Imatinib Respecto al Producto Innovador .” 2008. Web. 11 Dec 2019.

Vancouver:

Sasso Aguirre JA. Estudio de Biodisponibilidad Relativa de una Formulación Oral de Imatinib Respecto al Producto Innovador . [Internet] [Thesis]. Universidad de Chile; 2008. [cited 2019 Dec 11]. Available from: http://www.tesis.uchile.cl/tesis/uchile/2008/sasso_j/html/index-frames.html.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Sasso Aguirre JA. Estudio de Biodisponibilidad Relativa de una Formulación Oral de Imatinib Respecto al Producto Innovador . [Thesis]. Universidad de Chile; 2008. Available from: http://www.tesis.uchile.cl/tesis/uchile/2008/sasso_j/html/index-frames.html

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Texas Christian University

21. Weintraub, Marielle Kahn. Alleviation of central accumulation of amyloid-beta and prevention of cognitive dysfunction following peripheral inflammation.

Degree: PhD, 2014, Texas Christian University

 "Alzheimer's disease (AD) is characterized by neurodegeneration in regions of the adult brain, due to formation of amyloid-beta plaques and neurofibrillary tangles. Inflammation has been… (more)

Subjects/Keywords: Alzheimer's disease Treatment.; Amyloid beta-protein.; Imatinib.; Ibuprofen.; Exercise therapy.

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Weintraub, M. K. (2014). Alleviation of central accumulation of amyloid-beta and prevention of cognitive dysfunction following peripheral inflammation. (Doctoral Dissertation). Texas Christian University. Retrieved from https://repository.tcu.edu/handle/116099117/4557

Chicago Manual of Style (16th Edition):

Weintraub, Marielle Kahn. “Alleviation of central accumulation of amyloid-beta and prevention of cognitive dysfunction following peripheral inflammation.” 2014. Doctoral Dissertation, Texas Christian University. Accessed December 11, 2019. https://repository.tcu.edu/handle/116099117/4557.

MLA Handbook (7th Edition):

Weintraub, Marielle Kahn. “Alleviation of central accumulation of amyloid-beta and prevention of cognitive dysfunction following peripheral inflammation.” 2014. Web. 11 Dec 2019.

Vancouver:

Weintraub MK. Alleviation of central accumulation of amyloid-beta and prevention of cognitive dysfunction following peripheral inflammation. [Internet] [Doctoral dissertation]. Texas Christian University; 2014. [cited 2019 Dec 11]. Available from: https://repository.tcu.edu/handle/116099117/4557.

Council of Science Editors:

Weintraub MK. Alleviation of central accumulation of amyloid-beta and prevention of cognitive dysfunction following peripheral inflammation. [Doctoral Dissertation]. Texas Christian University; 2014. Available from: https://repository.tcu.edu/handle/116099117/4557


Université Paris-Sud – Paris XI

22. Locher, Clara. Optimisation d’une stratégie thérapeutique antitumorale conventionnelle par association à une immunothérapie : etude de phase I combinant l’Imatinib à l’Interleukine-2 : Optimisation of a targeted therapy by combining with a immunotherapy : phase 1 clinical trial of the co-administration of Imatinib and interleukin-2.

Degree: Docteur es, Onco-immunologie, 2013, Université Paris-Sud – Paris XI

Chef de file des inhibiteurs de tyrosines kinase, l’Imatinib Mesylate (IM) a révolutionné la prise en charge de la leucémie myéloïde chronique et des tumeurs… (more)

Subjects/Keywords: Cancer; Immunothérapie; Imatinib mésylate; Interleukine-2; Pharmacocinétiques; Cellules NK; Tumeurs stromales gastro-intestinales; Pronostic; Cancer; Immunotherapy; Imatinib mesylate; Interleukin-2; Pharmacokinetics; NK cells; Gastrointestinal sarcoma; Prognosis

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Locher, C. (2013). Optimisation d’une stratégie thérapeutique antitumorale conventionnelle par association à une immunothérapie : etude de phase I combinant l’Imatinib à l’Interleukine-2 : Optimisation of a targeted therapy by combining with a immunotherapy : phase 1 clinical trial of the co-administration of Imatinib and interleukin-2. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2013PA11T027

Chicago Manual of Style (16th Edition):

Locher, Clara. “Optimisation d’une stratégie thérapeutique antitumorale conventionnelle par association à une immunothérapie : etude de phase I combinant l’Imatinib à l’Interleukine-2 : Optimisation of a targeted therapy by combining with a immunotherapy : phase 1 clinical trial of the co-administration of Imatinib and interleukin-2.” 2013. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed December 11, 2019. http://www.theses.fr/2013PA11T027.

MLA Handbook (7th Edition):

Locher, Clara. “Optimisation d’une stratégie thérapeutique antitumorale conventionnelle par association à une immunothérapie : etude de phase I combinant l’Imatinib à l’Interleukine-2 : Optimisation of a targeted therapy by combining with a immunotherapy : phase 1 clinical trial of the co-administration of Imatinib and interleukin-2.” 2013. Web. 11 Dec 2019.

Vancouver:

Locher C. Optimisation d’une stratégie thérapeutique antitumorale conventionnelle par association à une immunothérapie : etude de phase I combinant l’Imatinib à l’Interleukine-2 : Optimisation of a targeted therapy by combining with a immunotherapy : phase 1 clinical trial of the co-administration of Imatinib and interleukin-2. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2013. [cited 2019 Dec 11]. Available from: http://www.theses.fr/2013PA11T027.

Council of Science Editors:

Locher C. Optimisation d’une stratégie thérapeutique antitumorale conventionnelle par association à une immunothérapie : etude de phase I combinant l’Imatinib à l’Interleukine-2 : Optimisation of a targeted therapy by combining with a immunotherapy : phase 1 clinical trial of the co-administration of Imatinib and interleukin-2. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2013. Available from: http://www.theses.fr/2013PA11T027


Université Paris-Sud – Paris XI

23. Levescot, AnaÏs. L’hypothèse d’un contrôle extrinsèque de la leucémie myéloïde chronique : place des lymphocytes iNKT et de la cytokine/alarmine IL-3 : The hypothesis of an extrinsic control of Chronic Myeloid Leukemia : role of iNKT cells and the cytokine/alarmin IL-33.

Degree: Docteur es, Immunologie, 2013, Université Paris-Sud – Paris XI

Les traitements actuels de la leucémie myéloïde chronique (LMC) ne permettent pas d’éliminer la totalité des cellules leucémiques. Dans le but de développer un traitement… (more)

Subjects/Keywords: CML; BCR-ABL; IFN-α; Imatinib; INKT; Cellules progénitrices CD34+; IL-33; ST2; CML; BCR-ABL; IFN-α; Imatinib; INKT; CD34+ progenitors; IL-33; ST2

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Levescot, A. (2013). L’hypothèse d’un contrôle extrinsèque de la leucémie myéloïde chronique : place des lymphocytes iNKT et de la cytokine/alarmine IL-3 : The hypothesis of an extrinsic control of Chronic Myeloid Leukemia : role of iNKT cells and the cytokine/alarmin IL-33. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2013PA114835

Chicago Manual of Style (16th Edition):

Levescot, AnaÏs. “L’hypothèse d’un contrôle extrinsèque de la leucémie myéloïde chronique : place des lymphocytes iNKT et de la cytokine/alarmine IL-3 : The hypothesis of an extrinsic control of Chronic Myeloid Leukemia : role of iNKT cells and the cytokine/alarmin IL-33.” 2013. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed December 11, 2019. http://www.theses.fr/2013PA114835.

MLA Handbook (7th Edition):

Levescot, AnaÏs. “L’hypothèse d’un contrôle extrinsèque de la leucémie myéloïde chronique : place des lymphocytes iNKT et de la cytokine/alarmine IL-3 : The hypothesis of an extrinsic control of Chronic Myeloid Leukemia : role of iNKT cells and the cytokine/alarmin IL-33.” 2013. Web. 11 Dec 2019.

Vancouver:

Levescot A. L’hypothèse d’un contrôle extrinsèque de la leucémie myéloïde chronique : place des lymphocytes iNKT et de la cytokine/alarmine IL-3 : The hypothesis of an extrinsic control of Chronic Myeloid Leukemia : role of iNKT cells and the cytokine/alarmin IL-33. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2013. [cited 2019 Dec 11]. Available from: http://www.theses.fr/2013PA114835.

Council of Science Editors:

Levescot A. L’hypothèse d’un contrôle extrinsèque de la leucémie myéloïde chronique : place des lymphocytes iNKT et de la cytokine/alarmine IL-3 : The hypothesis of an extrinsic control of Chronic Myeloid Leukemia : role of iNKT cells and the cytokine/alarmin IL-33. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2013. Available from: http://www.theses.fr/2013PA114835

24. Delord, Marc. Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition : Pharmacogenetics of Imatinib in Chronic Myeloid Leukemia etInterval Censored Competing Risks Data.

Degree: Docteur es, Santé publique - biostatistiques, 2015, Paris Saclay

Le traitement de la leucémie myéloïde chronique (LMC) par imatinib est un succès de thérapie ciblée en oncologie. Le principe de cette thérapie est de… (more)

Subjects/Keywords: Leucémie myéloïde chronique; Imatinib; Pharmacogénétique; Niveau de preuve; Imputation multiple; Censure par intervalles informative; Chronic myeloid leukemia; Imatinib; Pharmacogenetics; Level of evidence; Multiple imputation; Informative interval censoring

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Delord, M. (2015). Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition : Pharmacogenetics of Imatinib in Chronic Myeloid Leukemia etInterval Censored Competing Risks Data. (Doctoral Dissertation). Paris Saclay. Retrieved from http://www.theses.fr/2015SACLS075

Chicago Manual of Style (16th Edition):

Delord, Marc. “Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition : Pharmacogenetics of Imatinib in Chronic Myeloid Leukemia etInterval Censored Competing Risks Data.” 2015. Doctoral Dissertation, Paris Saclay. Accessed December 11, 2019. http://www.theses.fr/2015SACLS075.

MLA Handbook (7th Edition):

Delord, Marc. “Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition : Pharmacogenetics of Imatinib in Chronic Myeloid Leukemia etInterval Censored Competing Risks Data.” 2015. Web. 11 Dec 2019.

Vancouver:

Delord M. Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition : Pharmacogenetics of Imatinib in Chronic Myeloid Leukemia etInterval Censored Competing Risks Data. [Internet] [Doctoral dissertation]. Paris Saclay; 2015. [cited 2019 Dec 11]. Available from: http://www.theses.fr/2015SACLS075.

Council of Science Editors:

Delord M. Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition : Pharmacogenetics of Imatinib in Chronic Myeloid Leukemia etInterval Censored Competing Risks Data. [Doctoral Dissertation]. Paris Saclay; 2015. Available from: http://www.theses.fr/2015SACLS075

25. Erp, Petronella Hubertha van. Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib.

Degree: 2009, Department of Clinical Pharmacy and Toxicology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University

Het doel van het in dit proefschrift beschreven onderzoek was meer kennis te vergaren over de farmacokinetiek van imatinib en sunitinib in patiënten met kanker. Ook zijn verschillende mogelijkheden onderzocht om de therapie beter op de individuele patiënt af te stemmen en daarmee over- en onderdoseringen te voorkomen.

Subjects/Keywords: Farmacodynamiek; Farmacokinetiek; Farmacologie; Imatinib; Sunitinib; Farmacodynamiek; Farmacokinetiek; Farmacologie; Imatinib; Sunitinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Erp, P. H. v. (2009). Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib. (Doctoral Dissertation). Department of Clinical Pharmacy and Toxicology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University. Retrieved from http://hdl.handle.net/1887/14515

Chicago Manual of Style (16th Edition):

Erp, Petronella Hubertha van. “Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib.” 2009. Doctoral Dissertation, Department of Clinical Pharmacy and Toxicology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University. Accessed December 11, 2019. http://hdl.handle.net/1887/14515.

MLA Handbook (7th Edition):

Erp, Petronella Hubertha van. “Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib.” 2009. Web. 11 Dec 2019.

Vancouver:

Erp PHv. Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib. [Internet] [Doctoral dissertation]. Department of Clinical Pharmacy and Toxicology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University; 2009. [cited 2019 Dec 11]. Available from: http://hdl.handle.net/1887/14515.

Council of Science Editors:

Erp PHv. Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib. [Doctoral Dissertation]. Department of Clinical Pharmacy and Toxicology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University; 2009. Available from: http://hdl.handle.net/1887/14515


Linköping University

26. Hillberg, Paulina. Development of a quantitative chromatographic method for the determination of Imatinib and its main metabolite in human plasma.

Degree: Chemistry and Biology, 2009, Linköping University

  The objective of this master thesis was to develop an analytical method for the quantification of the cancer drug Imatinib and its main metabolite… (more)

Subjects/Keywords: Imatinib; HPLC-UV; LC-MS; analytical chemistry; CML; Analytical chemistry; Analytisk kemi

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Hillberg, P. (2009). Development of a quantitative chromatographic method for the determination of Imatinib and its main metabolite in human plasma. (Thesis). Linköping University. Retrieved from http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56627

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Hillberg, Paulina. “Development of a quantitative chromatographic method for the determination of Imatinib and its main metabolite in human plasma.” 2009. Thesis, Linköping University. Accessed December 11, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56627.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Hillberg, Paulina. “Development of a quantitative chromatographic method for the determination of Imatinib and its main metabolite in human plasma.” 2009. Web. 11 Dec 2019.

Vancouver:

Hillberg P. Development of a quantitative chromatographic method for the determination of Imatinib and its main metabolite in human plasma. [Internet] [Thesis]. Linköping University; 2009. [cited 2019 Dec 11]. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56627.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Hillberg P. Development of a quantitative chromatographic method for the determination of Imatinib and its main metabolite in human plasma. [Thesis]. Linköping University; 2009. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56627

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

27. Carvalho, Ana Raquel da Silva Gonçalves. Pesquisa e quantificação do transcrito BCR-ABL em amostras de sangue total, neutrófilos e células CD34+: sua relação com a resposta à terapêutica.

Degree: 2018, RCAAP

 Introdução: Atualmente, o tratamento da Leucemia mielóide crónica (LMC) baseia-se na utilização de inibidores tirosina-cinase que inibem a proteína oncogénica BCR-ABL. A avaliação da resposta… (more)

Subjects/Keywords: Leucemia Mieloide Crónica; Inibidores das tirosina-quinases; Imatinib; Neutrófilos; CD34+; Ciências Médicas

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Carvalho, A. R. d. S. G. (2018). Pesquisa e quantificação do transcrito BCR-ABL em amostras de sangue total, neutrófilos e células CD34+: sua relação com a resposta à terapêutica. (Thesis). RCAAP. Retrieved from https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/22718

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Carvalho, Ana Raquel da Silva Gonçalves. “Pesquisa e quantificação do transcrito BCR-ABL em amostras de sangue total, neutrófilos e células CD34+: sua relação com a resposta à terapêutica.” 2018. Thesis, RCAAP. Accessed December 11, 2019. https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/22718.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Carvalho, Ana Raquel da Silva Gonçalves. “Pesquisa e quantificação do transcrito BCR-ABL em amostras de sangue total, neutrófilos e células CD34+: sua relação com a resposta à terapêutica.” 2018. Web. 11 Dec 2019.

Vancouver:

Carvalho ARdSG. Pesquisa e quantificação do transcrito BCR-ABL em amostras de sangue total, neutrófilos e células CD34+: sua relação com a resposta à terapêutica. [Internet] [Thesis]. RCAAP; 2018. [cited 2019 Dec 11]. Available from: https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/22718.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Carvalho ARdSG. Pesquisa e quantificação do transcrito BCR-ABL em amostras de sangue total, neutrófilos e células CD34+: sua relação com a resposta à terapêutica. [Thesis]. RCAAP; 2018. Available from: https://www.rcaap.pt/detail.jsp?id=oai:comum.rcaap.pt:10400.26/22718

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

28. Vivona, Douglas. Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de  resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica.

Degree: PhD, Análises Clínicas, 2014, University of São Paulo

 A leucemia mieloide crônica (LMC) é uma expansão clonal da célula tronco hematopoética, traduzindo-se por hiperplasia mieloide, leucocitose, neutrofilia, basofilia e esplenomegalia. O cromossomo Filadélfia… (more)

Subjects/Keywords: ABCB1; ABCB1; Imatinib; Imatinibe; Leucemia mielóide; Myeloid leukemia; P-gp; P-gp; SLC22A1; SLC22A1

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Vivona, D. (2014). Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de  resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica. (Doctoral Dissertation). University of São Paulo. Retrieved from http://www.teses.usp.br/teses/disponiveis/9/9136/tde-18032014-131945/ ;

Chicago Manual of Style (16th Edition):

Vivona, Douglas. “Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de  resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica.” 2014. Doctoral Dissertation, University of São Paulo. Accessed December 11, 2019. http://www.teses.usp.br/teses/disponiveis/9/9136/tde-18032014-131945/ ;.

MLA Handbook (7th Edition):

Vivona, Douglas. “Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de  resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica.” 2014. Web. 11 Dec 2019.

Vancouver:

Vivona D. Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de  resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica. [Internet] [Doctoral dissertation]. University of São Paulo; 2014. [cited 2019 Dec 11]. Available from: http://www.teses.usp.br/teses/disponiveis/9/9136/tde-18032014-131945/ ;.

Council of Science Editors:

Vivona D. Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de  resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica. [Doctoral Dissertation]. University of São Paulo; 2014. Available from: http://www.teses.usp.br/teses/disponiveis/9/9136/tde-18032014-131945/ ;


Texas Medical Center

29. Nolden, Laura. Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing.

Degree: PhD, 2011, Texas Medical Center

  Although gastrointestinal stromal tumor (GIST) is effectively treated with imatinib, there are a number of clinical challenges in the optimal treatment of these patients.… (more)

Subjects/Keywords: Gastrointestinal stromal tumor; GIST; imatinib mesylate; plasma level testing; KIT; KIT mutation; Choi criteria; Oncology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Nolden, L. (2011). Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing. (Doctoral Dissertation). Texas Medical Center. Retrieved from http://digitalcommons.library.tmc.edu/utgsbs_dissertations/139

Chicago Manual of Style (16th Edition):

Nolden, Laura. “Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing.” 2011. Doctoral Dissertation, Texas Medical Center. Accessed December 11, 2019. http://digitalcommons.library.tmc.edu/utgsbs_dissertations/139.

MLA Handbook (7th Edition):

Nolden, Laura. “Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing.” 2011. Web. 11 Dec 2019.

Vancouver:

Nolden L. Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing. [Internet] [Doctoral dissertation]. Texas Medical Center; 2011. [cited 2019 Dec 11]. Available from: http://digitalcommons.library.tmc.edu/utgsbs_dissertations/139.

Council of Science Editors:

Nolden L. Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing. [Doctoral Dissertation]. Texas Medical Center; 2011. Available from: http://digitalcommons.library.tmc.edu/utgsbs_dissertations/139


University of Alberta

30. Gordon, Marilyn H. The Tumor Suppressor RASSF1A Links Inflammation and Cancer.

Degree: PhD, Medical Sciences-Paediatrics, 2015, University of Alberta

 The tumor suppressor protein Ras association domain family 1A (RASSF1A) has roles in multiple signaling pathways including modulating apoptosis, the cell cycle, DNA damage, and… (more)

Subjects/Keywords: inflammation; inflammatory bowel disease; YAP; imatinib; RASSF1A; colon cancer; colitis; cancer; tyrosine kinases

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Gordon, M. H. (2015). The Tumor Suppressor RASSF1A Links Inflammation and Cancer. (Doctoral Dissertation). University of Alberta. Retrieved from https://era.library.ualberta.ca/files/cv979v316k

Chicago Manual of Style (16th Edition):

Gordon, Marilyn H. “The Tumor Suppressor RASSF1A Links Inflammation and Cancer.” 2015. Doctoral Dissertation, University of Alberta. Accessed December 11, 2019. https://era.library.ualberta.ca/files/cv979v316k.

MLA Handbook (7th Edition):

Gordon, Marilyn H. “The Tumor Suppressor RASSF1A Links Inflammation and Cancer.” 2015. Web. 11 Dec 2019.

Vancouver:

Gordon MH. The Tumor Suppressor RASSF1A Links Inflammation and Cancer. [Internet] [Doctoral dissertation]. University of Alberta; 2015. [cited 2019 Dec 11]. Available from: https://era.library.ualberta.ca/files/cv979v316k.

Council of Science Editors:

Gordon MH. The Tumor Suppressor RASSF1A Links Inflammation and Cancer. [Doctoral Dissertation]. University of Alberta; 2015. Available from: https://era.library.ualberta.ca/files/cv979v316k

[1] [2] [3]

.